BioNTech at a Crossroads: ASCO Data Looms as Shareholders Vote on Board Expansion

BioNTech faces shareholder vote on board expansion amid Q1 loss of €532M, stock decline, and upcoming Phase 2 Pumitamig data at ASCO that will test its oncology pivot.

BioNTech shareholders head to the ballot box on Friday, but the real verdict on the company’s radical pivot into oncology won’t come until late May. The immediate agenda for the annual general meeting is a proposed expansion of the supervisory board from six to eight members, with two new oncologists and clinical development specialists joining the fold. Investors will also decide on a new authorized capital of roughly €129 million, equivalent to half of the existing share capital. Management is asking for firepower to fund the transition from pandemic hero to cancer-fighting biotech.

The financial pain of that transition is stark. BioNTech reported a net loss of approximately €532 million for the first quarter, on revenue of just €118 million — a 24% miss against analyst expectations. The company is standing by its full-year revenue guidance of €2 billion to €2.3 billion, but earnings visibility remains poor. A proposed dividend is off the table; instead, nearly €6.9 billion in retained earnings will be carried forward to fuel research.

To shore up shareholder confidence, the board has authorized a share buyback program of up to $1 billion, to be executed through open-market purchases. The move has done little to stem the selling so far. BioNTech’s stock hovers around €80, down roughly 5% over the past month and more than 20% off its 52-week high. The shares are trading just below their 50-day moving average, a technical signal that has market watchers on edge.

Adding to the uncertainty, co-founders Ugur Sahin and Özlem Türeci are preparing to exit the operating business by the end of 2026, moving into management of a separate entity where BioNTech will contribute its mRNA technologies for a minority stake. The announcement triggered an 18% single-day slide in March. The supervisory board is now scouting for successors, and Friday’s vote to add two specialists with deep clinical backgrounds is the first concrete step in that succession plan.

The next major catalyst arrives at the end of May, when BioNTech presents Phase 2 data for Pumitamig, its most advanced oncology candidate, at the American Society of Clinical Oncology (ASCO) meeting. The drug is being tested head-to-head against the established standard-of-care, pembrolizumab, in a lung cancer study. A strong readout would give credibility to the company’s long-stated ambition of bringing multiple cancer therapies to market by 2030.

Analyst opinion is split. Goldman Sachs remains bullish with a buy rating, while Leerink Partners has slashed its price target to $94, expressing skepticism about the chances of success in a separate cancer trial. The Pumitamig results will not be the final word, but for a company burning through cash as its Covid-19 franchise fades, they represent the most tangible proof point yet that its oncology gamble is more than just a plan on paper.